The announcement marks the disappointing end of a marathon effort by Oramed to develop an oral insulin formulation for type 2 diabetes struggling to control blood sugar on standard therapies and as an alternative to injections.
It exposes once again the challenges of making this delivery route a reality for large-molecule drugs, and puts a question mark over Oramed’s delivery technology, which is designed to protect the drug in the stomach by encapsulating the molecule and delivering it alongside enzyme inhibitors and permeation enhancers.
